Cynosure Group LLC Makes New $319,000 Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Cynosure Group LLC bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the first quarter, Holdings Channel.com reports. The firm bought 7,254 shares of the company’s stock, valued at approximately $319,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of AMPH. YHB Investment Advisors Inc. purchased a new stake in Amphastar Pharmaceuticals during the 1st quarter valued at about $27,000. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $28,000. Principal Securities Inc. purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $34,000. Quadrant Capital Group LLC lifted its position in Amphastar Pharmaceuticals by 27.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after buying an additional 223 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Amphastar Pharmaceuticals by 115.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock worth $150,000 after buying an additional 1,300 shares in the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, May 22nd. Piper Sandler reissued an “overweight” rating and issued a $71.00 price objective on shares of Amphastar Pharmaceuticals in a report on Thursday, June 27th. Finally, StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 13th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $66.00.

Insider Transactions at Amphastar Pharmaceuticals

In related news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the transaction, the director now owns 78,409 shares in the company, valued at $3,246,132.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO William J. Peters sold 3,596 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at approximately $3,851,635.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the sale, the director now directly owns 78,409 shares in the company, valued at approximately $3,246,132.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,596 shares of company stock valued at $313,544. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Trading Up 1.0 %

AMPH traded up $0.40 on Tuesday, hitting $41.07. The company had a trading volume of 57,697 shares, compared to its average volume of 414,369. The company has a current ratio of 2.18, a quick ratio of 1.72 and a debt-to-equity ratio of 0.88. The firm has a market cap of $2.01 billion, a P/E ratio of 14.18, a PEG ratio of 0.70 and a beta of 0.80. The company’s fifty day moving average price is $40.60 and its 200 day moving average price is $45.27. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.20. The company had revenue of $171.84 million for the quarter, compared to analyst estimates of $171.13 million. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. As a group, equities analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.6 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.